Research Article
Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib
Table 1
International Prognostic Scoring System.
| Variable (1 point each) | Risk group |
| Age > 65 years | Low risk: 0 points | Constitutional symptoms | Intermediate-1 risk: 1 point | Hemoglobin < 10 g/dL | Intermediate-2 risk: 2 points | Leukocyte count > 25 × 109/L | High risk: ≥ 3 points | Circulating blasts ≥ 1% | |
|
|